Prices as of 2026/10/30 close
Company comparison · Mid-Tier Pharma & Drug Discovery
Kaken is the bigger company, with revenue of ¥76.9B — 4.2x Peptide Dream's ¥18.5B.
Kaken earns more on each yen of sales, with an operating margin of -1.2% — 25.9 points above Peptide Dream (-27.1%).
Revenue growth in the latest results: Kaken −18.3%, Peptide Dream −60.3%.
Peptide Dream pays more on average — ¥11.7M against ¥8.75M at Kaken.
Over the past year the shares moved Kaken +5.2%, Peptide Dream −28.4%.
Head-to-head wins12 metrics
One win per metric for the company with the best value. Metrics with no better or worse (P/E, average age, employees) are excluded.
ScaleInvestors
Kaken aheadKaken 3 : Peptide Dream 0
Revenue: Kaken ¥76.9B / Peptide Dream ¥18.5B
ProfitabilityInvestors
Kaken aheadKaken 2 : Peptide Dream 1
Operating margin: Kaken −1.2% / Peptide Dream −27.1%
GrowthInvestors
EvenKaken 1 : Peptide Dream 1
Revenue growth (YoY): Kaken −18.3% / Peptide Dream −60.3%
Stock & balance sheetInvestors
EvenKaken 1 : Peptide Dream 1
Share price, 1 year: Kaken +5.2% / Peptide Dream −28.4%
Pay & workforceJob seekers
EvenKaken 1 : Peptide Dream 1
Average salary: Kaken ¥8.75M / Peptide Dream ¥11.7M
| Metric | Kaken | Peptide Dream | Gap |
|---|---|---|---|
| Revenue | ◎¥76.9B | ¥18.5B | 4.2x |
| Operating profit | ◎−¥899M | −¥5.0B | |
| Net income | ◎¥2.1B | −¥3.7B |
| Metric | Kaken | Peptide Dream | Gap |
|---|---|---|---|
| Operating margin | ◎−1.2% | −27.1% | 25.9pt |
| Net margin | ◎2.8% | −20.2% | 23.0pt |
| ROE | 1.4% | — | |
| Revenue per employee | ¥71M | ◎¥118M | 1.7x |
| Metric | Kaken | Peptide Dream | Gap |
|---|---|---|---|
| Revenue growth (YoY) | ◎−18.3% | −60.3% | 42.0pt |
| Revenue CAGR | — | +18.6% | |
| Guidance: revenue growthnext FY plan | +16.9% | ◎+72.8% | 55.8pt |
| Metric | Kaken | Peptide Dream | Gap |
|---|---|---|---|
| Share price, 1 year | ◎+5.2% | −28.4% | 33.7pt |
| Share price, 3 months | −2.0% | ◎+19.2% | 21.2pt |
| P/E (trailing)lower = cheaper | 67.7x | — | |
| Equity ratio | 82.8% | — | |
| Share price (close) | ¥3,830 | ¥1,117 |
◎ marks the best value for each metric. Revenue and profit are from the latest full-year earnings release; share prices are closing-price references; P/E = latest close ÷ trailing EPS. For banks and some other financials, revenue means ordinary income.
| Metric | Kaken | Peptide Dream | Gap |
|---|---|---|---|
| Average salary | ¥8.75M | ◎¥11.7M | ¥2.94M |
| Starting salary (monthly) | ¥268,100 | — | |
| Average tenure | ◎17.3 yrs | 5.3 yrs | 12.0 |
| Average age | 41.9 | 39.7 | 2.2 |
| Employees | 1,086 | 157 | 6.9x |
Average salary is for the reporting (parent) company and is affected by average age and job mix. Holding companies with few employees are left out of the salary comparison.
Close (Oct 30, 2026)
¥3,830+5.2% (1Y)
Kaken +5.2% over 1Y. Compared: Peptide Dream -28.4%.
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Each line shows the % change from the start of the period. Updated Oct 30, 2026.
Kaken2 segments
Peptide Dream2 segments
AAverage annual salary from the securities filings: Peptide Dream ¥11.7M, Kaken ¥8.75M. Peptide Dream pays the most. Averages also depend on staff age and job mix, so check the average age too (Kaken 41.9, Peptide Dream 39.7).
ARevenue in the latest results: Kaken ¥76.9B, Peptide Dream ¥18.5B. Kaken is the bigger company, with revenue of ¥76.9B — 4.2x Peptide Dream's ¥18.5B.
AOperating margins: Kaken -1.2%, Peptide Dream -27.1%. Kaken turns the highest share of sales into operating profit.
AShare price change over the past year (closing prices, for reference): Kaken +5.2%, Peptide Dream −28.4%. Kaken has risen the most.
Comparing 2 companies (up to 4)
Sources: earnings releases (kessan tanshin), annual securities reports and other public information. Share prices are closing-price references, not real-time. Our data may contain errors; investment decisions are your own responsibility.
